Universiteit Leiden

nl en


Semisynthetic Glycopeptide Antibiotics

  • E. van Groesen
woensdag 12 oktober 2022
Rapenburg 73
2311 GJ Leiden


  • Prof.dr. N.I. Martin


The accelerated appearance of drug-resistant pathogens continues to present a growing threat to modern medicine’s capacity to fight infectious disease. A recent Lancet study estimates that in 2019 antimicrobial resistance (AMR) was directly responsible for a staggering 1.27 million deaths worldwide and further associated with an estimated 4.95 million deaths. Among the pathogens that contribute most to this global burden of AMR, drug resistant variants of the Gram-positive species S. aureus and S. pneumonia are responsible for a combined 0.5 million annual deaths. Historically, treatment of such Gram-positive infections has relied upon the glycopeptide family of antibiotics, typified by vancomycin, as a last line of defense. In recent years however, vancomycin-resistance has emerged highlighting the importance of developing next generation glycopeptides with enhanced antibacterial activities and improved safety profiles. In this thesis, a variety of semisynthetic glycopeptides were developed and assessed for their antimicrobial activity, using different strategies. The guanidino lipoglycopeptides (described in Chapter 2-3) have potent in vitro and in vivo activity against Gram-positive strains and have the potential to become the new best in class. The vancomyxins (Chapter 4) and the vancomycin-sideromycins (Chapter 5) take a different approach by targeting Gram-negative strains, which normally are not sensitive to glycopeptide antibiotics. Overall, this thesis describes diverse strategies to tack antimicrobial resistance to both Gram-positive and Gram-negative strains.


Ongeveer een week na de promotie zijn proefschriften van Leidse promovendi digitaal beschikbaar via het Leids Repositorium. De proefschriften op deze site zijn vrij toegankelijk. Alleen in sommige gevallen rust er een tijdelijk embargo op een proefschrift en wordt het proefschrift pas later volledig beschikbaar gesteld.

Persvragen (alleen journalisten)

071 - 527 1521

Algemene informatie

Bureau Pedel
071 527 7211

Deze website maakt gebruik van cookies.  Meer informatie.